Log in

Relevant bibliographies by topics / MMPI-2 / Journal articles

To see the other types of publications on this topic, follow the link: MMPI-2.

Journal articles on the topic 'MMPI-2'

Author: Grafiati

Published: 4 June 2021

Last updated: 15 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'MMPI-2.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Balasa, Rodica, Ciurba Bianca, Voidezan Septimiu, et al. "The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders." CNS & Neurological Disorders - Drug Targets 17, no. 6 (2018): 464–72. http://dx.doi.org/10.2174/1871527317666180703102536.

Full text

Abstract:

Background: In the lymphocyte migration across the blood-brain barrier (BBB) in multiple sclerosis (MS), matrix metalloproteinases (MMPs) play an important role in the degradation of the basal membrane. Natalizumab (NAT), a monoclonal antibody, binds to the alpha-4 (α4) integrin leading to BBB impermeability. Approximately 30% of NAT-treated patients show clinical or MRI signs of BBB disruption. Objective: To determine whether NAT significantly influences the MMPs serum levels and to what extent these could be used as biomarkers in relapsing-remitting MS (RRMS) patients. Materials and Methods: This prospective study over a period of 8 months of NAT treatment, included 30 RRMS patients (mean age 38 ± 6 years; mean MS duration 12 ± 5 years), of which ten were initially naive to NAT and 15 were healthy controls. We determined the serum levels of the MMPs Panel (MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP12, and MMP13) quantified by a multiplex method at the beginning and end of the study. Results: After 8 months of NAT treatment, a statistically significant decrease was found in MMP9, MMP2, MMP3, MMP8, and MMP10 levels. Relapses during the study were correlated with a variation of MMP12 and MMP13 serum levels. MMP9 had the most numerous correlations with the EDSS score, Rio score, and duration of NAT treatment. MMPs signature (the sum of all MMPs) and the MMP9/MMP2 ratio significantly decreased during the study. Conclusion: 1. The serum level of MMP9 significantly decreased by NAT treatment and correlates with MS activity; 2. After eight months of NAT treatment, the MMPs signature and the MMP9/MMP2 ratio decreased; 3. MMP9 might be used as a biomarker in MS patients treated with NAT.

APA, Harvard, Vancouver, ISO, and other styles

2

Bartnykaitė, Agnė, Aistė Savukaitytė, Justina Bekampytė, et al. "The Role of Matrix Metalloproteinase Single-Nucleotide Polymorphisms in the Clinicopathological Properties of Breast Cancer." Biomedicines 10, no. 8 (2022): 1891. http://dx.doi.org/10.3390/biomedicines10081891.

Full text

Abstract:

(1) Background. Breast cancer is the leading cancer type among women. Despite convenient diagnostics at early stages, there is a need for continuous monitoring to predict more aggressive or recurring breast cancer forms. The evidence suggests that the detection of genetic biomarkers could help in improving disease management and reduce mortality. Matrix metalloproteinases (MMPs) are a large family of enzymes that perform physiologically relevant functions and have the potential properties to be biomarkers for cancer assessment. We aimed to evaluate the contribution and association of single-nucleotide polymorphisms (SNPs) in MMP genes (MMP1, MMP2, MMP3, MMP7, MMP8, MMP9) with clinicopathological breast-cancer features. (2) Methods. In this study, 100 breast cancer patients were genotyped by polymerase chain reaction–restriction fragment length polymorphism methodology (PCR–RFLP). (3) Results. The presence of the MMP7 rs11568818 A allele was associated with lower chances for poorly differentiated breast cancer. The lower possibility for HER2-positive breast cancer was associated with the presence of the MMP9 rs3918242 C allele. (4) Conclusions. These results indicate that MMP7 rs11568818 and MMP9 rs3918242 are potential biomarkers for the anticipation of breast cancer aggressiveness.

APA, Harvard, Vancouver, ISO, and other styles

3

Ikonomidis, John S., Jennifer W. Hendrick, Andrea M. Parkhurst, et al. "Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition." American Journal of Physiology-Heart and Circulatory Physiology 288, no. 1 (2005): H149—H158. http://dx.doi.org/10.1152/ajpheart.00370.2004.

Full text

Abstract:

Alterations in matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) have been implicated in adverse left ventricular (LV) remodeling after myocardial infarction (MI). However, the direct mechanistic role of TIMPs in the post-MI remodeling process has not been completely established. The goal of this project was to define the effects of altering endogenous MMP inhibitory control through combined genetic and pharmacological approaches on post-MI remodeling in mice. This study examined the effects of MMP inhibition (MMPi) with PD-166793 (30 mg·kg−1·day−1) on LV geometry and function (conductance volumetry) after MI in wild-type (WT) mice and mice deficient in the TIMP-1 gene [TIMP-1 knockout (TIMP1-KO)]. At 3 days after MI (coronary ligation), mice were randomized into four groups: WT-MI/MMPi ( n = 10), TIMP1-KO-MI/MMPi ( n = 10), WT-MI ( n = 22), and TIMP1-KO-MI ( n = 23). LV end-diastolic volume (EDV) and ejection fraction were determined 14 days after MI. Age-matched WT ( n = 20) and TIMP1-KO ( n = 28) mice served as reference controls. LVEDV was similar under control conditions in WT and TIMP1-KO mice (36 ± 2 and 40 ± 2 μl, respectively) but was greater in TIMP1-KO-MI than in WT-MI mice (48 ± 2 vs. 61 ± 5 μl, P < 0.05). LVEDV was reduced from MI-only values in WT-MI/MMPi and TIMP1-KO-MI/MMPi mice (42 ± 2 and 36 ± 2 μl, respectively, P < 0.05) but was reduced to the greatest degree in TIMP1-KO mice ( P < 0.05). LV ejection fraction was reduced in both groups after MI and increased in TIMP1-KO-MI/MMPi, but not in WT-MI/MMPi, mice. These unique results demonstrated that myocardial TIMP-1 plays a regulatory role in post-MI remodeling and that the accelerated myocardial remodeling induced by TIMP-1 gene deletion can be pharmacologically “rescued” by MMP inhibition. These results define the importance of local endogenous control of MMP activity with respect to regulating LV structure and function after MI.

APA, Harvard, Vancouver, ISO, and other styles

4

Gömöri, Kamilla, Tamara Szabados, Éva Kenyeres, et al. "Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors." International Journal of Molecular Sciences 21, no. 19 (2020): 6990. http://dx.doi.org/10.3390/ijms21196990.

Full text

Abstract:

Background: We recently developed novel matrix metalloproteinase-2 (MMP-2) inhibitor small molecules for cardioprotection against ischemia/reperfusion injury and validated their efficacy in ischemia/reperfusion injury in cardiac myocytes. The aim of the present study was to test our lead compounds for cardioprotection in vivo in a rat model of acute myocardial infarction (AMI) in the presence or absence of hypercholesterolemia, one of the major comorbidities affecting cardioprotection. Methods: Normocholesterolemic adult male Wistar rats were subjected to 30 min of coronary occlusion followed by 120 min of reperfusion to induce AMI. MMP inhibitors (MMPI)-1154 and -1260 at 0.3, 1, and 3 µmol/kg, MMPI-1248 at 1, 3, and 10 µmol/kg were administered at the 25th min of ischemia intravenously. In separate groups, hypercholesterolemia was induced by a 12-week diet (2% cholesterol, 0.25% cholic acid), then the rats were subjected to the same AMI protocol and single doses of the MMPIs that showed the most efficacy in normocholesterolemic animals were tested in the hypercholesterolemic animals. Infarct size/area at risk was assessed at the end of reperfusion in all groups by standard Evans blue and 2,3,5-triphenyltetrazolium chloride (TTC) staining, and myocardial microvascular obstruction (MVO) was determined by thioflavine-S staining. Results: MMPI-1154 at 1 µmol/kg, MMPI-1260 at 3 µmol/kg and ischemic preconditioning (IPC) as the positive control reduced infarct size significantly; however, this effect was not seen in hypercholesterolemic animals. MVO in hypercholesterolemic animals decreased by IPC only. Conclusions: This is the first demonstration that MMPI-1154 and MMPI-1260 showed a dose-dependent infarct size reduction in an in vivo rat AMI model; however, single doses that showed the most efficacy in normocholesterolemic animals were abolished by hypercholesterolemia. The further development of these promising cardioprotective MMPIs should be continued with different dose ranges in the study of hypercholesterolemia and other comorbidities.

APA, Harvard, Vancouver, ISO, and other styles

5

Butler, Georgina S., Richard A. Dean, Eric M. Tam, and Christopher M. Overall. "Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding." Molecular and Cellular Biology 28, no. 15 (2008): 4896–914. http://dx.doi.org/10.1128/mcb.01775-07.

Full text

Abstract:

ABSTRACT Broad-spectrum matrix metalloproteinase (MMP) inhibitors (MMPI) were unsuccessful in cancer clinical trials, partly due to side effects resulting from limited knowledge of the full repertoire of MMP substrates, termed the substrate degradome, and hence the in vivo functions of MMPs. To gain further insight into the degradome of MMP-14 (membrane type 1 MMP) an MMPI, prinomastat (drug code AG3340), was used to reduce proteolytic processing and ectodomain shedding in human MDA-MB-231 breast cancer cells transfected with MMP-14. We report a quantitative proteomic evaluation of the targets and effects of the inhibitor in this cell-based system. Proteins in cell-conditioned medium (the secretome) and membrane fractions with levels that were modulated by the MMPI were identified by isotope-coded affinity tag (ICAT) labeling and tandem mass spectrometry. Comparisons of the expression of MMP-14 with that of a vector control resulted in increased MMP-14/vector ICAT ratios for many proteins in conditioned medium, indicating MMP-14-mediated ectodomain shedding. Following MMPI treatment, the MMPI/vehicle ICAT ratio was reversed, suggesting that MMP-14-mediated shedding of these proteins was blocked by the inhibitor. The reduction in shedding or the release of substrates from pericellular sites in the presence of the MMPI was frequently accompanied by the accumulation of the protein in the plasma membrane, as indicated by high MMPI/vehicle ICAT ratios. Considered together, this is a strong predictor of biologically relevant substrates cleaved in the cellular context that led to the identification of many undescribed MMP-14 substrates, 20 of which we validated biochemically, including DJ-1, galectin-1, Hsp90α, pentraxin 3, progranulin, Cyr61, peptidyl-prolyl cis-trans isomerase A, and dickkopf-1. Other proteins with altered levels, such as Kunitz-type protease inhibitor 1 and beta-2-microglobulin, were not substrates in biochemical assays, suggesting an indirect affect of the MMPI, which might be important in drug development as biomarkers or, in preclinical phases, to predict systemic drug actions and adverse side effects. Hence, this approach describes the dynamic pattern of cell membrane ectodomain shedding and its perturbation upon metalloproteinase drug treatment.

APA, Harvard, Vancouver, ISO, and other styles

6

Blau, Theodore H. "The MMPI, MMPI-2, and MMPI-A in Court (Book)." Journal of Personality Assessment 65, no. 1 (1995): 190–92. http://dx.doi.org/10.1207/s15327752jpa6501_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bachna, K. "MMPI/MMPI-2 Comparisons of Amnesic Patients." Archives of Clinical Neuropsychology 13, no. 6 (1998): 535–42. http://dx.doi.org/10.1016/s0887-6177(97)00043-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bachna, K., M. A. Sieggreen, L. Cermak, W. Penk, and M. O'Connor. "MMPI/MMPI-2:Comparisons of Amnesic Patients." Archives of Clinical Neuropsychology 13, no. 6 (1998): 535–42. http://dx.doi.org/10.1093/arclin/13.6.535.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

MINO, Yukiko, Takaki MAKINO, Shota KASAI, and Tooru OGUCHI. "MMPI-2 Restructured Clinical Scales and MMPI-2 Restructured Form." Proceedings of the Annual Convention of the Japanese Psychological Association 75 (September 15, 2011): 2PM005. http://dx.doi.org/10.4992/pacjpa.75.0_2pm005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Parisien, Michel. "DU MMPI AU MMPI-2-RF/MMPI-3 : L’ABANDON DES SUBTERFUGES." Revue québécoise de psychologie 43, no. 3 (2022): 217. http://dx.doi.org/10.7202/1094898ar.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Gaston, Michele F., W. M. Nelson, Kathleen J. Hart, and Roza Rojdev. "The Equivalence of the MMPI and MMPI-2." Assessment 1, no. 4 (1994): 415–18. http://dx.doi.org/10.1177/107319119400100411.

Full text

Abstract:

Since the MMPI-2 was developed, it has been assumed that the new version is comparable to the MMPI. This study explored the comparability of the MMPI and MMPI-2 by examining the similarities between their respective T-score means, profile configurations, score distributions, and rank-order correlations on the standard 3 validity and 10 clinical scales. Eighty-four undergraduate students were randomly assigned to one of four groups in a test-retest (4-month interval) counterbalanced design–MMPI/MMPI, MMPI/MMPI-2, MMPI-2/MMPI, or MMPI-2/MMPI-2. In this college sample, MMPI-2 mean scores tended to be lower than respective MMPI counterpart scales, which is consistent with previous research. There were notable similarities between the MMPI and the MMPI-2 in terms of profile characteristics, score distributions, and rank ordering of scales. Using these criteria, the equivalency of the two forms was generally supported and further equivalency issues are discussed.

APA, Harvard, Vancouver, ISO, and other styles

12

Brophy, Alfred L. "The MMPI Suspiciousness Scale on the MMPI-2." Psychological Reports 79, no. 3_suppl (1996): 1306. http://dx.doi.org/10.2466/pr0.1996.79.3f.1306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hwang Soon Taeg, 조혜선, and 남지숙. "Comparisons between Profiles of MMPI and MMPI-2." Korean Journal of Clinical Psychology 29, no. 2 (2010): 525–39. http://dx.doi.org/10.15842/kjcp.2010.29.2.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Gross, Kristin, Megan D. Keyes, and Roger L. Greene. "Assessing Depression With the MMPI and MMPI-2." Journal of Personality Assessment 75, no. 3 (2000): 464–77. http://dx.doi.org/10.1207/s15327752jpa7503_07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Lewis, Ronald F., and Karen K. Downey. "MMPI/MMPI-2 critical items for panic symptoms." Journal of Anxiety Disorders 6, no. 3 (1992): 275–83. http://dx.doi.org/10.1016/0887-6185(92)90039-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Lyons, Judith A., and Terence M. Keane. "Keane PTSD scale: MMPI and MMPI-2 update." Journal of Traumatic Stress 5, no. 1 (1992): 111–17. http://dx.doi.org/10.1002/jts.2490050112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Butcher, James N., John R. Graham, and Yossef S. Ben-Porath. "Methodological problems and issues in MMPI, MMPI-2, and MMPI-A research." Psychological Assessment 7, no. 3 (1995): 320–29. http://dx.doi.org/10.1037/1040-3590.7.3.320.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Parisien, Michel. "From MMPI to MMPI-2-RF/MMPI-3: The abandonment of subterfuge." Quantitative Methods for Psychology 19, no. 1 (2023): 47–58. http://dx.doi.org/10.20982/tqmp.19.1.p047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Van Der Heijden, P. T., J. I. M. Egger, and J. J. L. Derksen. "Comparability of Scores on the MMPI–2–RF Scales Generated With the MMPI–2 and MMPI–2–RF Booklets." Journal of Personality Assessment 92, no. 3 (2010): 254–59. http://dx.doi.org/10.1080/00223891003670208.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Williams, Carolyn L., and Stephen J. Lally. "MMPI-2, MMPI-2-RF, and MMPI-A administrations (2007–2014): Any evidence of a “new standard?”." Professional Psychology: Research and Practice 48, no. 4 (2017): 267–74. http://dx.doi.org/10.1037/pro0000088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Gumbiner, Jann, and John Flowers. "Sex Differences on the MMPI-1 and MMPI-2." Psychological Reports 81, no. 2 (1997): 479–82. http://dx.doi.org/10.2466/pr0.1997.81.2.479.

Full text

Abstract:

This study compared sex differences on the MMPI-2 to those previously found on the MMPI-1. Statistically significant differences were found with men (n = 66) showing higher mean raw scale scores on antisocial (men = 10.00, women = 7.15), authority problems (men = 4.58, women = 3.14), admission of addiction (men = 3.58, women = 2.74), amorality (men = 2.30, women = 1.61), and Type A (men = 8.24, women = 7.71). Women ( n= 132) showed higher mean raw scale scores on Hypochondriasis, Depression, Hysteria, Paranoia, Depression subscale, N affection, Health Concerns, and Somatic Complaints. With a few exceptions, these general patterns are consistent with previous research.

APA, Harvard, Vancouver, ISO, and other styles

22

Morrison, Thomas L., Daniel W. Edwards, Herbert N. Weissman, Ronald Allen, and Arnold DeLaCruz. "Comparing MMPI and MMPI-2 Profiles: Replication and Integration." Assessment 2, no. 1 (1995): 39–46. http://dx.doi.org/10.1177/1073191195002001004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

GUMBINER, JANN. "SEX DIFFERENCES ON THE MMPI-1 AND MMPI-2." Psychological Reports 81, no. 6 (1997): 479. http://dx.doi.org/10.2466/pr0.81.6.479-482.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Caldwell, Alex B. "Whither Goest Our Redoubtable Mentor, the MMPI/MMPI--2?" Journal of Personality Assessment 68, no. 1 (1997): 47–68. http://dx.doi.org/10.1207/s15327752jpa6801_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Aaronson, Arthur L., Oran B. Dent, and Christopher D. Kline. "Cross-validation of MMPI and MMPI-2 predictor scales." Journal of Clinical Psychology 52, no. 3 (1996): 311–15. http://dx.doi.org/10.1002/(sici)1097-4679(199605)52:3<311::aid-jclp8>3.0.co;2-u.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Bow, James N., James (Jay) Flens, and Jonathan W. Gould. "Commentary: MMPI-2 Readability." Journal of Child Custody 3, no. 1 (2006): 71–75. http://dx.doi.org/10.1300/j190v03n01_05.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Nichols, David S. "MMPI-2 MicroGenie? (Software)." Journal of Personality Assessment 56, no. 3 (1991): 545–46. http://dx.doi.org/10.1207/s15327752jpa5603_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tarescavage, Anthony M., Michael L. Alosco, Yossef S. Ben-Porath, Arcangela Wood, and Lynn Luna-Jones. "Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) Scores Generated From the MMPI-2 and MMPI-2-RF Test Booklets." Assessment 22, no. 2 (2014): 188–97. http://dx.doi.org/10.1177/1073191114537347.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Mota, Joana, Rosa Direito, João Rocha, et al. "Lupinus albus Protein Components Inhibit MMP-2 and MMP-9 Gelatinolytic Activity In Vitro and In Vivo." International Journal of Molecular Sciences 22, no. 24 (2021): 13286. http://dx.doi.org/10.3390/ijms222413286.

Full text

Abstract:

Matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) are regarded as important clinical targets due to their nodal-point role in inflammatory and oncological diseases. Here, we aimed at isolating and characterizing am MMP-2 and-9 inhibitor (MMPI) from Lupinus albus and at assessing its efficacy in vitro and in vivo. The protein was isolated using chromatographic and 2-D electrophoretic procedures and sequenced by using MALDI-TOF TOF and MS/MS analysis. In vitro MMP-2 and 9 inhibitions were determined on colon adenocarcinoma (HT29) cells, as well as by measuring the expression levels of genes related to these enzymes. Inhibitory activities were also confirmed in vivo using a model of experimental TNBS-induced colitis in mice, with oral administrations of 15 mg·kg−1. After chromatographic and electrophoretic isolation, the L. albus MMP-9 inhibitor was found to comprise a large fragment from δ-conglutin and, to a lower extent, small fragments of β-conglutin. In vitro studies showed that the MMPI successfully inhibited MMP-9 activity in a dose-dependent manner in colon cancer cells, with an IC50 of 10 µg·mL−1 without impairing gene expression nor cell growth. In vivo studies showed that the MMPI maintained its bioactivities when administered orally and significantly reduced colitis symptoms, along with a very significant inhibition of MMP-2 and -9 activities. Overall, results reveal a novel type of MMPI in lupine that is edible, proteinaceous in nature and soluble in water, and effective in vivo, suggesting a high potential application as a nutraceutical or a functional food in pathologies related to abnormally high MMP-9 activity in the digestive system.

APA, Harvard, Vancouver, ISO, and other styles

30

Girasek, Hunor, Alexandra Soós, Henrietta Janicsák, Dóra Dudás, and Melinda Reinhardt. "Változások és újítások a Minnesota Multiphasic Personality Inventory-2 (MMPI-2) pszichodiagnosztikai tesztben." Magyar Pszichológiai Szemle 78, no. 1 (2023): 135–56. http://dx.doi.org/10.1556/0016.2023.00028.

Full text

Abstract:

BevezetésA Minnesota Multiphasic Inventory (MMPI) Magyarországon az 1970-es évek óta használatos pszichodiagnosztikai mérőeszköz, melynek második kiadása (MMPI-2) 1989-ben jelent meg a nemzetközi használatban, Magyarországon pedig 2009-ben készült el az adaptációja.CélkitűzésJelen tanulmány célja, hogy bemutassa az MMPI-2-ben megjelent változásokat, újításokat és a teszt előnyeit a korábbi változatához képest.KövetkeztetésekA téma-összefoglaló tanulmány rávilágít, hogy az MMPI-2 kifejlesztése nemcsak új normatív mintát, de nyelvi-stilisztikai megújulást is hozott. Ezenfelül a korábbi Validitási és Klinikai skálák mellett olyan új skálák is megjelentek, mint az Újrastrukturált klinikai skálák, a Tartalmi skálák és a személyiségpszichopatológia mérésére alkalmas PSY-5 skálák. Megtörtént továbbá a Kiegészítő skálák revíziója, illetve új Kiegészítő skálák bevezetése és új Validitási skálák kifejlesztése is.KonklúzióA változtatások részletes számbavétele rámutat arra, hogy az MMPI újrasztenderdizálása során kialakított MMPI-2 jóval átfogóbb, egyben differenciáltabb értelmezést kínál a különböző mentális zavarok és pszichopatológiai jelenségek megértése szempontjából, mint az eredeti változat. Kitekintésként pedig ismertetésre kerül a nemzetközi gyakorlatba már bevezetett két új MMPI-fejlesztés, az MMPI-2-Resturctured Form (MMPI-2-RF) és az MMPI-3 is.

APA, Harvard, Vancouver, ISO, and other styles

31

Sellbom, Martin, R. Michael Bagby, Shauna Kushner, Lena C. Quilty, and Lindsay E. Ayearst. "Diagnostic Construct Validity of MMPI-2 Restructured Form (MMPI-2-RF) Scale Scores." Assessment 19, no. 2 (2011): 176–86. http://dx.doi.org/10.1177/1073191111428763.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Meyers, John E., Ronald M. Miller, Nathan A. Haws, et al. "An Adaptation of the MMPI-2 Meyers Index for the MMPI-2-RF." Applied Neuropsychology: Adult 21, no. 2 (2013): 148–54. http://dx.doi.org/10.1080/09084282.2013.780173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sinnett, E. Robert, Michael C. Holen, and William L. Albott. "Profile Validity Standards for MMPI and MMPI–2 F Scales." Psychological Reports 84, no. 1 (1999): 288–90. http://dx.doi.org/10.2466/pr0.1999.84.1.288.

Full text

Abstract:

Although numerous indices of validity have been developed for the MMPI and MMPI–2, interest in the F scale and its variants continues, especially among practicing clinicians. The use of the binomial for assessing standards for random answering and possibly for judgments of malingering offers another approach for the interpretation of F-scale scores. The theoretical binomial distribution and Monte Carlo data are in accord. Cut-off scores of 24 for the MMPI and 23 for the MMPI–2 suggest random responses, and scores of 40 and 37, respectively, suggest clinical interpretation rather than randomness of responding.

APA, Harvard, Vancouver, ISO, and other styles

34

Wetzler, Scott, and Douglas Marlowe. "“Faking Bad” on the MMPI, MMPI-2, and Millon-II." Psychological Reports 67, no. 3_suppl (1990): 1117–18. http://dx.doi.org/10.2466/pr0.1990.67.3f.1117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Larrabee, G. J. "Somatic malingering on the MMPI/MMPI-2 in litigating subjects." Archives of Clinical Neuropsychology 12, no. 4 (1997): 353–54. http://dx.doi.org/10.1093/arclin/12.4.353a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

WETZLER, SCOTT. "'FAKING BAD' ON THE MMPI, MMPI-2, AND MILLON-II." Psychological Reports 67, no. 7 (1990): 1117. http://dx.doi.org/10.2466/pr0.67.7.1117-1118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

WETZLER, SCOTT. ""FAKING BAD" ON THE MMPI, MMPI-2, AND MILLON-II." Psychological Reports 67, no. 8 (1990): 1117. http://dx.doi.org/10.2466/pr0.67.8.1117-1118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ben-Porath, Yossef S., and James N. Butcher. "The comparability of MMPI and MMPI-2 scales and profiles." Psychological Assessment: A Journal of Consulting and Clinical Psychology 1, no. 4 (1989): 345–47. http://dx.doi.org/10.1037/1040-3590.1.4.345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Albrecht, Nettie N., F. Suzanne Talbert, Patrick A. Boudewyns, et al. "A comparison of MMPI and MMPI-2 in PTSD assessment." Journal of Clinical Psychology 50, no. 4 (1994): 578–85. http://dx.doi.org/10.1002/1097-4679(199407)50:4<578::aid-jclp2270500413>3.0.co;2-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Legan, Leone, and Robert J. Craig. "Correspondence of MMPI and MMPI-2 with chemically dependent patients." Journal of Clinical Psychology 52, no. 5 (1996): 589–97. http://dx.doi.org/10.1002/(sici)1097-4679(199609)52:5<589::aid-jclp15>3.0.co;2-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Brown, Jacob R., William H. Menton, and Yossef S. Ben-Porath. "Development and validation of a method for deriving MMPI-3 scores from MMPI-2/MMPI-2-RF item responses." Psychological Assessment 36, no. 11 (2024): 665–79. http://dx.doi.org/10.1037/pas0001341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Butcher, James N., and Kirsten Hostetler. "Abbreviating MMPI item administration: What can be learned from the MMPI for the MMPI--2?" Psychological Assessment 2, no. 1 (1990): 12–21. http://dx.doi.org/10.1037/1040-3590.2.1.12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Corrales, Monica L., Francisco Gomez, Sonia Mendoza, Jose J. Cabiya, Guadalupe X. Ayala, and Roberto J. Velasquez. "MMPI–2 and MMPI–A Research with U.S. Latinos: A Bibliography." Psychological Reports 83, no. 3 (1998): 1027–33. http://dx.doi.org/10.2466/pr0.1998.83.3.1027.

Full text

Abstract:

This bibliography presents a comprehensive listing of all research conducted on U.S. Latinos, including Puerto Ricans, with the MMPI–2 and MMPI–A beginning in 1989. A total of 52 studies and 6 additional resources are listed. Researchers and clinicians could use this bibliography for the culturally appropriate application of the MMPI–2/MMPI–A with this growing population.

APA, Harvard, Vancouver, ISO, and other styles

44

Archer, Elizabeth M., Leigh D. Hagan, Janelle Mason, Richard Handel, and Robert P. Archer. "MMPI-2-RF Characteristics of Custody Evaluation Litigants." Assessment 19, no. 1 (2011): 14–20. http://dx.doi.org/10.1177/1073191110397469.

Full text

Abstract:

The Minnesota Multiphasic Personality Inventory-2–Restructured Form (MMPI-2-RF) is a 338-item objective self-report measure drawn from the 567 items of the MMPI-2. Although there is a substantial MMPI-2 literature regarding child custody litigants, there has been only one previously published study using MMPI-2-RF data in this population that focused on Validity scales L-r and K-r. The current study evaluated the MMPI-2-RF results of 344 child custody litigants and showed substantial consistency between T-score elevations typically found on MMPI-2 Validity scales L and K, and comparable elevations for MMPI-2-RF validity scales L-r and K-r. Mean T-scores well within normal limits characterized results for clinical scales on both instruments. The RC scale intercorrelation patterns, and alpha coefficient values found for MMPI-2-RF scales in a custody population, were also found to be very similar to those reported for other populations. Directions for future research are presented.

APA, Harvard, Vancouver, ISO, and other styles

45

Brophy, Alfred L. "MMPI and MMPI-2 Scores on the Cook-Medley Hostility Scale." Psychological Reports 80, no. 3_suppl (1997): 1087–90. http://dx.doi.org/10.2466/pr0.1997.80.3c.1087.

Full text

Abstract:

Raw-score means of the Cook-Medley Hostility scale are smaller in the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) normative group than in the MMPI normative group, and T scores are larger. The results contrast with those for the clinical scales but are consistent with results for some other scales. Reasons for the different patterns of MMPI and MMPI-2 scores are discussed.

APA, Harvard, Vancouver, ISO, and other styles

46

Казеко, Л. А., В. А. Захарова, and Ю. Д. Бенеш. "The Role of Matrix Metalloproteinases and Their Tissue Inhibitors in the Pathogenesis of Aggressive Periodontitis." Стоматология. Эстетика. Инновации, no. 4 (November 25, 2022): 329–36. http://dx.doi.org/10.34883/pi.2022.6.4.006.

Full text

Abstract:

Нарушение баланса между уровнями MMPs и TIMPs является одним из звеньев патогенеза патологии периодонта. Данные о том, какие именно MMPs играют решающую роль в определении характера течения периодонтитов, весьма противоречивы. Цель. Установить роль параметров стромальной экспрессии MMPs и TIMPs в биопсийном материале десен пациентов в патогенезе быстропрогрессирующего периодонтита. Материалы и методы. Исследован биопсийный материал десен 26 пациентов с быстропрогрессирующим характером течения периодонтита, окрашенный с использованием моноклональных антител к MMP (-1, -2, -8, -9, -13, -14) и TIMP (-1, -2). Морфометрический и статистический анализ выполнен с использованием AperioImageScopev12.4.0.5043, Statistica10.0, р<0,01. Результаты. В группе пациентов с быстропрогрессирующим периодонтитом имеют место сопоставимые или более низкие параметры позитивности экспрессии MMP8 (5%), MMP9 (0,6%) и ММР13 (10%) по сравнению с таковыми ТIMP1 (12,5%) и TIMP2 (42%). Высокие же параметры позитивности экспрессии ММР1 (78,5%), ММР2 (56,5%) и ММР14 (77,0%), которые в 4–9 раз превышали таковые TIMP1 и до 6 раз TIMP2, отражают низкую эффективность ингибирующего действия на них вышеназванных TIMPs и, вероятно, вносят основной вклад в агрессивное течение периодонтита. Заключение. Сравнительный анализ уровней экспрессии MMPs и TIMPs показал, что в группе пациентов с быстропрогрессирующим течением периодонтита в ответ на рост параметров экспрессии MMPs значимо повышается экспрессия как TIMP1, так и TIMP2 с более эффективным ингибированием ими MMP8, MMP9 и ММР13. Сохранение же значимо более высоких параметров экспрессии ММР1, ММР2 и ММР14 по сравнению с таковыми TIMP1 и TIMP2 является отражением дисбаланса их экспрессии и, вероятно, может иметь решающее значение в патогенезе быстропрогрессирующей деструкции периодонтальных тканей и утраты альвеолярной кости. The imbalance between MMPs and TIMPs levels is one of the links in the pathogenesis of periodontal pathology. The data on which MMPs play a crucial role in determining the type of periodontitis course are quite controversial. Purpose. To determine the parameters of stromal expression of MMPs and TIMPs in the gingival biopsy material of patients with aggressive periodontitis. Material and methods. The gingival biopsy from 26 patients with aggressive periodontitis (AgP, n=26) was analyzed. Morphometric and statistical analysis of MMPs (-1, -2, -8, -9, -13, -14) and TIMP1 expression was performed using AperioImageScope v12.4.0.5043, Statistica 10.0, p<0.05. Results. In the AgP group, there are comparable or lower parameters of positive expression of MMP8 (5%), MMP9 (0.6%) and MMP13 (10%) compared with those of TIMP1 (12.5%) and TIMP2 (42%). The high parameters of the positive expression of MMP1 (78.5%), MMP2 (56.5%) and MMP14 (77.0%), which were 4–9 times higher than those of TIMP1 and up to 6 times TIMP2, reflect the low effectiveness of the inhibitory effect of the above-mentioned TIMPs on them and probably make the main contribution to the aggressive course of periodontitis. Conclusion. Comparative analysis of MMPs and TIMPs expression levels showed that in the AgP group, in response to an increase in MMPs expression parameters, the expression of both TIMP1 and TIMP2 significantly increased with more effective inhibition of MMP8, MMP9 and MMP13. The preservation of significantly higher expression parameters of MMP1, MMP2 and MMP14 compared to those of TIMP1 and TIMP2 is a reflection of the imbalance of their expression and, probably, may be crucial in the pathogenesis of progressive destruction of periodontal tissues and loss of alveolar bone.

APA, Harvard, Vancouver, ISO, and other styles

47

Locke, Dona E. C. "Interpreting the MMPI-2-RF." Clinical Neuropsychologist 27, no. 2 (2012): 339–41. http://dx.doi.org/10.1080/13854046.2012.742291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Taylor, Linda D. "MMPI-2 and ballet majors." Personality and Individual Differences 22, no. 4 (1997): 521–26. http://dx.doi.org/10.1016/s0191-8869(96)00220-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Butcher, James N., John R. Graham, and Raymond D. Fowler. "SPECIAL SERIES: THE MMPI-2*." Journal of Personality Assessment 57, no. 2 (1991): 203–4. http://dx.doi.org/10.1207/s15327752jpa5702_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Derksen, J. J. L. "MMPI-2-schalen en farmacotherapie." GZ - Psychologie 3, no. 3 (2011): 20–28. http://dx.doi.org/10.1007/s41480-011-0027-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!